The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.
 
Arjun Vasant Balar
Honoraria - Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Genentech/Roche; Merck; Pfizer/EMD Serono
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Horizon Pharma; Inovio Pharmaceuticals; Lilly; Merck Sharp & Dohme; Novartis; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst); US Patent No: 15/226,474 files on 7/1/15 (Inst)
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Biocept; Bristol-Myers Squibb; Clovis Oncology; Dendreon; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genentech; Merck; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Genentech
Research Funding - AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst)
 
Andrea Necchi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Merck Sharp & Dohme; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre; Roche
 
Maria De Santis
Honoraria - Astellas Pharma; Bayer; Novartis; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ferring; GlaxoSmithKline; Ipsen; Janssen; Merck Sharp & Dohme; Oncogenex; Pierre Fabre; Roche/Genentech; Sanofi; Synthon; Takeda
Research Funding - Pierre Fabre
Travel, Accommodations, Expenses - Bayer; Ipsen; Janssen; Sanofi
 
Lei Pang
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck; Merck (I)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Stephen Michael Keefe
Employment - Merck Sharp & Dohme
 
Kevin O'Hayer
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Yufan Zhao
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Ronald De Wit
Honoraria - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Consulting or Advisory Role - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Research Funding - Bayer (Inst); Sanofi (Inst)